openPR Logo
Press release

Acute Ischemic Stroke Pipeline Insight 2025: 20+ Companies Advancing Next-Gen Neuroprotective and Thrombolytic Therapies | DelveInsight

07-28-2025 07:24 PM CET | Health & Medicine

Press release from: DelveInsight

Acute Ischemic Stroke Pipeline

Acute Ischemic Stroke Pipeline

DelveInsight's "Acute Ischemic Stroke - Pipeline Insight, 2025" offers a comprehensive look into the evolving therapeutic landscape of one of the leading causes of long-term disability and death globally. Acute ischemic stroke (AIS), caused by a sudden blockage of blood flow to the brain, remains a major unmet medical challenge despite current standards of care such as thrombolysis (tPA) and mechanical thrombectomy. The limited treatment window and risks of hemorrhage have driven the need for safer, more effective interventions.

Recent pipeline advances focus on expanding the therapeutic time window and improving outcomes through neuroprotective agents, novel thrombolytics, and combination strategies. Promising candidates in mid-to-late-stage trials include multi-target agents aimed at reducing neuronal injury, reperfusion therapies with enhanced clot-dissolving capabilities, and adjuncts to mechanical thrombectomy that may extend treatment benefits. Notably, biologics, peptides, and small molecules targeting inflammation, excitotoxicity, and blood-brain barrier stabilization are gaining momentum.

Several assets have received fast-track and orphan designations from regulatory authorities, highlighting the urgency and potential of innovation in this space. Enhanced imaging-guided approaches, biomarker-driven trial designs, and AI-integrated diagnostics are also redefining the endpoints of stroke trials. As of 2025, over 20+ companies are actively developing therapies targeting AIS, with a shared vision to reduce time-to-treatment, enhance recovery, and ultimately reshape the prognosis for stroke patients worldwide.

Interested in learning more about the current treatment landscape and the key drivers shaping the Acute Ischemic Stroke pipeline? Click here: https://www.delveinsight.com/report-store/acute-ischemic-stroke-ais-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the Acute Ischemic Stroke Pipeline Report
• DelveInsight's acute ischemic stroke pipeline analysis depicts a strong space with 20+ active players working to develop 25+ pipeline drugs for acute ischemic stroke treatment.
• The leading acute ischemic stroke companies include Tasly Pharmaceutical, Revalesio Corporation, Avilex Pharma, GNT Pharma, Biogen, AptaTargets, NC Medical Research, Prolong Pharmaceuticals, Saillant Therapeutics, TargED Biopharmaceuticals, and others are evaluating their lead assets to improve the acute ischemic stroke treatment landscape.
• Key acute ischemic stroke pipeline therapies in various stages of development include Prourokinase recombinant, RNS60, AVLX 144, Nelonemdaz, BIIB131, ApTOLL, NCS 01, PP-007, ST-01, Microlyse, and others.
• In July 2025, Imperative Care, Inc. announced that the FDA granted 510(k) clearance for their latest innovation in ischemic stroke treatment-the new Zoom 7X Catheter for aspiration thrombectomy procedures-and reported the first patient cases using this device.
• In March 2025, Perfuze, a leading medical device company dedicated to advancing stroke treatment, announced that it has received FDA 510(k) clearance for its ZiplineTM Access Catheters. This regulatory milestone strengthens Perfuze's growing portfolio of innovative neurovascular devices, empowering physicians to treat acute ischemic strokes with greater speed, ease, and precision. In addition, Perfuze has secured €22 million in follow-on funding
• In March 2025, the U.S. Food and Drug Administration approved TNKase (tenecteplase), a thrombolytic agent, for the treatment of acute ischemic stroke in adults.

Request a sample and discover the recent breakthroughs happening in the acute ischemic stroke pipeline landscape at https://www.delveinsight.com/report-store/acute-ischemic-stroke-ais-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Acute Ischemic Stroke Overview
Acute ischemic stroke occurs when a blood clot blocks a vessel supplying blood to the brain, leading to sudden loss of neurological function. This interruption in blood flow deprives brain tissue of oxygen and nutrients, causing cell damage or death. It is one of the most common types of stroke and requires immediate medical intervention to restore circulation and minimize long-term disability.

Prompt treatment options for acute ischemic stroke include intravenous thrombolysis and mechanical thrombectomy, which aim to dissolve or physically remove the clot. Rapid diagnosis and intervention are critical to improving patient outcomes, as brain cells begin to die within minutes of oxygen deprivation. Advances in stroke care, including improved imaging and novel devices, continue to enhance the ability to save brain tissue and reduce the impact of this devastating condition.

Find out more about Acute Ischemic Stroke medication at https://www.delveinsight.com/report-store/acute-ischemic-stroke-ais-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Acute Ischemic Stroke Treatment Analysis: Drug Profile
Prourokinase recombinant: Tasly Pharmaceutical
Prourokinase recombinant is an investigational drug developed by Tasly Pharmaceutical for treating Acute Ischemic Stroke. This recombinant human (rh) Pro-UK is a novel thrombolytic agent that selectively activates plasminogen on the fibrin surface, leading to targeted clot breakdown. Compared to other thrombolytics, it offers greater efficacy and fewer adverse effects. Its thrombolytic therapy has demonstrated reliable curative effects and high safety in patients with acute myocardial infarction. The drug is currently in Phase III clinical trials for Acute Ischemic Stroke treatment.

RNS60: Revalesio Corporation
RNS60 is being developed as a disease-modifying and potentially restorative therapy for neurological disorders. It works by activating intracellular signaling pathways to enhance mitochondrial biogenesis and function while reducing inflammation. RNS60 protects neurons and oligodendrocytes and helps regulate immune cell activity to restore balance in the nervous system. The U.S. FDA has granted RNS60 Orphan Drug and Fast Track designations for ALS. It is presently in Phase II clinical development for Acute Ischemic Stroke.

Learn more about the novel and emerging Acute Ischemic Stroke pipeline therapies at https://www.delveinsight.com/report-store/acute-ischemic-stroke-ais-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Acute Ischemic Stroke Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Intravenous
• Subcutaneous
• Oral
• Intramuscular

By Molecule Type
• Monoclonal antibody
• Small molecule
• Peptide

Scope of the Acute Ischemic Stroke Pipeline Report
• Coverage: Global
• Key Acute Ischemic Stroke Companies: Tasly Pharmaceutical, Revalesio Corporation, Avilex Pharma, GNT Pharma, Biogen, AptaTargets, NC Medical Research, Prolong Pharmaceuticals, Saillant Therapeutics, TargED Biopharmaceuticals, and others.
• Key Acute Ischemic Stroke Pipeline Therapies: Prourokinase recombinant, RNS60, AVLX 144, Nelonemdaz, BIIB131, ApTOLL, NCS 01, PP-007, ST-01, Microlyse, and others.

To dive deep into rich insights for drugs used for Acute Ischemic Stroke treatment, visit: https://www.delveinsight.com/report-store/acute-ischemic-stroke-ais-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Acute Ischemic Stroke Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Acute Ischemic Stroke Pipeline Therapeutics
6. Acute Ischemic Stroke Pipeline: Late-Stage Products (Phase III)
7. Acute Ischemic Stroke Pipeline: Mid-Stage Products (Phase II)
8. Acute Ischemic Stroke Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Acute Ischemic Stroke Pipeline Insight 2025: 20+ Companies Advancing Next-Gen Neuroprotective and Thrombolytic Therapies | DelveInsight here

News-ID: 4123399 • Views:

More Releases from DelveInsight

Homozygous Familial Hypercholesterolemia Pipeline Insight 2025: RNA-Based Therapies, Gene Editing, and Next-Gen Lipid-Lowering Agents Drive New Hope for the Ultra-Rare Cholesterol Disorder | DelveInsight
Homozygous Familial Hypercholesterolemia Pipeline Insight 2025: RNA-Based Therap …
DelveInsight's "Homozygous Familial Hypercholesterolemia (HoFH) - Pipeline Insight, 2025" offers a deep analysis of the evolving therapeutic landscape for one of the most severe and genetically driven lipid disorders. HoFH, affecting ~1 in 300K individuals worldwide, is characterized by markedly elevated LDL-C levels from birth and rapid progression to premature atherosclerotic cardiovascular disease. Despite statins, ezetimibe, and PCSK9 inhibitors, most HoFH patients remain undertreated due to minimal or absent LDL
Lamellar Ichthyosis Pipeline Insight 2025: Topical Gene Therapies, Barrier Repair Innovations, and Novel Retinoids Reshape Management of Rare Congenital Skin Disorders | DelveInsight
Lamellar Ichthyosis Pipeline Insight 2025: Topical Gene Therapies, Barrier Repai …
DelveInsight's "Lamellar Ichthyosis - Pipeline Insight, 2025" provides an in-depth analysis of the emerging therapeutic landscape for this debilitating autosomal recessive skin disorder. Characterized by generalized, plate-like scaling and erythroderma from birth, Lamellar Ichthyosis (LI) stems primarily from TGM1 gene mutations that impair epidermal barrier formation. With no curative treatment and current care relying heavily on emollients, keratolytics, and systemic retinoids, the need for disease-modifying therapies remains urgent. The 2025 pipeline
Anemia in Chronic Kidney Disease Pipeline Insight 2025: HIF-PH Inhibitors, Novel ESAs, and Oral Agents Reshape the Treatment Paradigm | DelveInsight
Anemia in Chronic Kidney Disease Pipeline Insight 2025: HIF-PH Inhibitors, Novel …
DelveInsight's "Anemia in Chronic Kidney Disease (CKD) - Pipeline Insight, 2025" explores the dynamic therapeutic landscape targeting one of the most burdensome comorbidities in CKD. Affecting millions of dialysis and non-dialysis patients worldwide, CKD-related anemia is primarily driven by insufficient erythropoietin production and iron dysregulation. Traditional erythropoiesis-stimulating agents (ESAs), though widely used, are limited by administration route, cardiovascular risks, and inconsistent efficacy in inflammatory states. The 2025 pipeline marks a major
Overactive Bladder Pipeline Insight 2025: Next-Gen Neuromodulation, Beta-3 Agonists, and Regenerative Therapies Redefine Bladder Control | DelveInsight
Overactive Bladder Pipeline Insight 2025: Next-Gen Neuromodulation, Beta-3 Agoni …
DelveInsight's "Overactive Bladder (OAB) - Pipeline Insight, 2025" evaluates the robust expansion in therapeutic options for this highly prevalent and quality-of-life-impacting condition. Affecting over 30 million people worldwide, OAB is defined by urinary urgency, frequency, and incontinence. Traditional anticholinergics and beta-3 agonists have limited adherence due to side effects like dry mouth, constipation, or cardiovascular concerns. The 2025 pipeline reflects a shift toward better-tolerated oral agents, minimally invasive devices, and

All 5 Releases


More Releases for Acute

Acute Lymphoblastic Leukemia Therapeutics Market Size, Acute Lymphoblastic Leuke …
Acute Lymphoblastic Leukemia Therapeutics Market Dynamics are clarified by an in-depth review of facts on current and emerging trends. To understand a resource, the paper uses Porter's five forces to examine the importance of numerous qualities such as understanding of suppliers and customers, dangers provided by various agents, competitive strength, and promising new businesses. precious. Furthermore, the study covers numerous firms' Acute Lymphoblastic Leukemia Therapeutics research data, benefit, gross margin,
Acute Conjunctivitis Treatment Market: The Future Insights Of Global Acute Conju …
Acute Conjunctivitis Treatment Market Acute Conjunctivitis Treatment Market, or pink eye, is an irritation or inflammation of the conjunctiva that covers the white part of the eyeball. It can be caused by allergies or a bacterial or viral infection. Acute Conjunctivitis Treatment Market can be highly communicable and can be spread easily by the contact with secretions of eye from the infected person. Conjunctivitis often resolves on its own, but
Acute Renal Failure (ARF) (Acute Kidney Injury) Global Clinical Trials Review, H …
ReportsWorldwide has announced the addition of a new report title Acute Renal Failure (ARF) (Acute Kidney Injury) Global Clinical Trials Review, H1, 2017 to its growing collection of premium market research reports. GlobalData's clinical trial report, “Acute Renal Failure (ARF) (Acute Kidney Injury) Global Clinical Trials Review, H1, 2017" provides an overview of Acute Renal Failure (ARF) (Acute Kidney Injury) clinical trials scenario. This report provides top line data relating to
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical T …
ReportsWorldwide has announced the addition of a new report title Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical Trials Review, H1, 2017 to its growing collection of premium market research reports. GlobalData's clinical trial report, “Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical Trials Review, H1, 2017" provides an overview of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) clinical trials scenario. This report provides top line data relating to
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Tri …
ReportsWorldwide has announced the addition of a new report title Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Trials Review, H1, 2017 to its growing collection of premium market research reports. GlobalData's clinical trial report, “Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Trials Review, H1, 2017" provides an overview of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) clinical trials scenario. This report provides top line data relating to
H2 2016 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeut …
Albany, New York, January 03, 2017: A recent forecast report focusing on the Acute Myelocytic Leukemia Market has been added to the wide portfolio of Market Research Hub (MRH). It is entitled as, “Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2016” which has been equipped by in-depth market examination with inputs from the industry experts. It covers the current market scenario and also its future growth